Corbus Pharmaceuticals Holdings, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CRBP Nasdaq 2836 www.corbuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss - Dec 11th, 2025 6:19 am
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - Dec 11th, 2025 5:00 am
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - Dec 10th, 2025 2:01 pm
Corbus Pharmaceuticals: Q3 Earnings Snapshot - Nov 12th, 2025 6:09 am
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - Nov 12th, 2025 6:00 am
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - Nov 6th, 2025 6:00 am
Corbus Pharmaceuticals Announces Pricing of Public Offering - Oct 31st, 2025 12:40 am
Corbus Pharmaceuticals Announces Proposed Public Offering - Oct 30th, 2025 2:31 pm
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 - Oct 18th, 2025 1:00 am
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 - Oct 14th, 2025 6:00 am
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium - Oct 7th, 2025 6:00 am
Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Invest In Growth? - Sep 25th, 2025 9:07 am
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 - Sep 22nd, 2025 6:00 am
FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma - Sep 16th, 2025 6:00 am
Corbus Pharmaceuticals: Q2 Earnings Snapshot - Aug 5th, 2025 6:11 am
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Aug 5th, 2025 6:00 am
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress - Jul 30th, 2025 6:00 am
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is largely controlled by institutional shareholders who own 51% of the company - Jul 20th, 2025 6:47 am
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity - Jun 30th, 2025 6:00 am
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab - Jun 25th, 2025 6:00 am